Immunomodulatory Effects of Molecular Hydrogen Therapy in Systemic Lupus Erythematosus With Pericarditis and Pleuritis: A Case Report.
Ting-Hao Tu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu · In vivo (Athens, Greece) · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In October 2024, molecular hydrogen supplementation was introduced as an adjuvant therapy. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in CASE REPORT: This is the case of a 49-year-old Taiwanese female diagnosed with SLE, alongside pericarditis, pleuritis, and multi-organ impairments. In October 2024, molecular hydrogen supplementation was introduced as an adjuvant therapy.
What the Researchers Studied
The researchers studied CASE REPORT: This is the case of a 49-year-old Taiwanese female diagnosed with SLE, alongside pericarditis, pleuritis, and multi-organ impairments.
What Effects Did Molecular Hydrogen Have?
To establish its clinical application, large-scale randomized controlled trials are essential to verify the efficacy and safety of molecular hydrogen therapy. In October 2024, molecular hydrogen supplementation was introduced as an adjuvant therapy. The authors concluded that further investigation into its clinical efficacy and safety is necessary for the development of treatment guidelines. Even though the immunomodulatory mechanism of molecular hydrogen therapy in autoimmune diseases remains unclear, this case study demonstrates that hydrogen therapy has positive influence on the percentage of Tregs, Tr1 cells, transitional B cells, and B cell subsets expressing Fas in the peripheral blood, offering novel insights into the therapeutic applications of molecular hydrogen.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was CASE REPORT: This is the case of a 49-year-old Taiwanese female diagnosed with SLE, alongside pericarditis, pleuritis, and multi-organ impairments.
Limitations and Safety
Reported limitations: However, a limitation of this case study is the absence of long-term follow-up, which is necessary to confirm the duration of immunomodulatory efficacy and to monitor possible adverse effects of hydrogen therapy.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.